Wall Street swoons over Amgen's D-mab future

It's been a long time since I've heard the words "love" and "Amgen" in one sentence, but that's the approach the Los Angeles Times took in covering Wall Street's enthusiastic response to D-mab's performance in a recent clinical trial. Oppenheimer's Bret Holley says the drug is on track to break the billion-dollar mark in 2010 with an approval possible in 2009. And that helped send shares of Amgen surging to a 14-month high.

- reaad the story from the Los Angeles Times

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.